Searched for
EREZ ISRAELI CEO
Dr Reddy’s aims to resume semaglutide supply by November after API fixDr Reddy's expects to resume semaglutide supplies by November after resolving quality issues. The company identified the root cause and pla...- Tariff hike by US will only increase drug prices: Dr Reddy's CEOUS tariff increases on generic medicines will lead to higher drug prices in India. Dr Reddy's Laboratories CEO Erez Israeli stated relocati...
- Dr Reddy’s pauses weight loss drug on quality fearsDr Reddy's Laboratories will halt semaglutide injection supplies until at least October. Unspecified impurities were identified during the ...
- Dr Reddy’s launches generic Semaglutide injection, popular weight-loss drug, in CanadaDr Reddy's Laboratories has launched its generic Semaglutide injection in Canada. This marks a significant step for the company in providin...
- Dr Reddy's gets Health Canada nod for generic semaglutide injectionDr Reddy's Laboratories has secured market authorization from Health Canada for its generic semaglutide injection. This marks a significant...
- Dr Reddy's plans to launch generic of Novo's weight-loss drug next year, CEO saysDr. Reddy's Laboratories intends to introduce a more affordable generic version of Novo Nordisk's popular weight-loss medication, Wegovy, i...
- Dr Reddy's unit ties up with Shanghai Henlius BiotechDr Reddy's Laboratories has partnered with Shanghai Henlius Biotech to develop and commercialize HLX15, a biosimilar to the cancer drug Dar...
- Alvotech, Dr. Reddy's ink pact for commercialisation of denosumabAlvotech and Dr. Reddy's partner for AVT03, a biosimilar to Prolia and Xgeva, treating osteoporosis and skeletal-related events. The agreem...
- Dr Reddy's Q1 Results: Net profit rises 18% YoY to Rs 1403 croreIndian drug company Dr Reddy's plans to use its net cash surplus of INR 5,000 crore ($670m) to fund acquisitions and innovations aiming at ...
- Dr Reddy's to acquire Mayne Pharma US generic portfolio for $105 millionUnder the terms of the agreement, Dr. Reddy’s will acquire the portfolio for an upfront payment of $90 million in cash, contingent payments...
- Dr Reddy's gearing up to get substantial slice of Revlimid generic opportunity in USRevlimid is a top-selling cancer drug from Bristol Myers Squibb. Its generic form, called lenalidomide, is seen as Dr Reddy's most anticipa...
- Submitted proposal to DCGI to test Sputnik Light as Covid booster dose: Dr Reddy's"As regards to Sputnik, we are now ready with capacities in India. We are working actively with the Government of India for registering Spu...
- Dr Reddy's lines up Rs 1,000 crore capex for current fiscal yearThe Hyderabad based firm invested about Rs 1,000 crore in the 2020-21 fiscal year.
- Like DRL, will Wipro too see a turnaround under expat CEO?Wipro’s board has taken a step in the right direction. Now, besides the skills and effectiveness of the incoming CEO, the freedom given to ...
- Why a new expat CEO may be good news for Dr Reddy’sDrug maker undergoing major changes under Erez Islraeli
- Chinese strategy: Dr Reddy's outsources part manufacturing to local partiesThe company which won the tender to market Olanzapine drug in China, is expected to launch it beginning next year, the official said. The p...
- DRL Q1 profit surges 45% YoY to Rs 663 crore; margins shrink 400 bpsAnalysts in an ET Now poll had anticipated Rs 481 crore profit.
- Dr Reddy's acquires a portfolio of 42 ANDAs in USThese products will require to be technology transferred and could be launched within the next one to two years.
- Dr Reddy's hires former Teva exec to lead the businessHis knowledge and experience from leading pharmaceutical businesses of scale will be valuable for our future growth,” said G.V. Prasad CEO ...
- Tatanet to deploy Israeli satellite network to serve SMEIndia's leading satellite service provider Tatanet has chosen Israel's Gilat Satellite Networks's broadband service to serve Small and Medi...
Load More
